Previous 10 | Next 10 |
home / stock / gild / gild articles
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc&n...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return...
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...